<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03126461</url>
  </required_header>
  <id_info>
    <org_study_id>STU 082016-058</org_study_id>
    <nct_id>NCT03126461</nct_id>
  </id_info>
  <brief_title>SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients</brief_title>
  <official_title>Phase 2 Trial of SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A one-arm, single center phase 2 trial of SAbR plus ipilimumab plus nivolumab in advanced&#xD;
      metastatic melanoma patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by&#xD;
      nivolumab 240 mg IV q 2wk until progression or intolerable toxicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    the project was never initiated and no participants were enrolled, it was closed permanently&#xD;
  </why_stopped>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of tumor size from baseline to follow up</measure>
    <time_frame>at 12, 24, 36 weeks</time_frame>
    <description>treatment response rate-RR based on RECISTv1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>at 12, 24, 36 weeks</time_frame>
    <description>disease control rate defined as response plus stable disease based on RECISTv1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related adverse events</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>programmed death ligand-1 (PD-L1) expression</measure>
    <time_frame>baseline, cycle 1 Day 1, and week 15</time_frame>
    <description>compare tumor PD-L1 expression at 3 time points</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>SAbR plus ipilimumab plus nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SAbR</intervention_name>
    <description>For patients treated on the &quot;GRID A&quot; regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the &quot;GRID B&quot; regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose.</description>
    <arm_group_label>SAbR plus ipilimumab plus nivolumab</arm_group_label>
    <other_name>Stereotactic ablative body radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>ipilimumab 3mg/kg IV q3wk x 4</description>
    <arm_group_label>SAbR plus ipilimumab plus nivolumab</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab 1 mg/kg IV q3wk x 4</description>
    <arm_group_label>SAbR plus ipilimumab plus nivolumab</arm_group_label>
    <other_name>Opdivo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of metastatic melanoma.&#xD;
&#xD;
          -  Any number of prior systemic therapeutic regimens including chemotherapy, pathway&#xD;
             inhibitors, biochemotherapy, investigational agents, and immunotherapies other than&#xD;
             ipilimumab, nivolumab or other CTLA-4, PD-1 or PD-L1 inhibitors.&#xD;
&#xD;
          -  Patients must have measurable disease in at least 2 non-radiated sites as defined by&#xD;
             RECIST v1.1. All sites must be evaluated within 4 weeks prior to registration.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Eligible for SABR to 1-5 sites of disease (Refer to 3.2.10)&#xD;
&#xD;
          -  Performance status ECOG 0-2.&#xD;
&#xD;
          -  Adequate organ and marrow function as defined below:&#xD;
&#xD;
               -  leukocytes ≥ 1,000/mcL&#xD;
&#xD;
               -  absolute neutrophil count ≥ 1,000/mcL&#xD;
&#xD;
               -  platelets ≥ 75,000/mcl&#xD;
&#xD;
               -  total bilirubin &lt; 2.5X institutional upper limit of normal or&#xD;
&#xD;
                    -  3 in subjects with Gilbert's Syndrome&#xD;
&#xD;
               -  AST(SGOT)/ALT(SPGT) ≤ 4 X institutional upper limit of normal&#xD;
&#xD;
               -  creatinine &lt; 4X institutional upper limit of normal&#xD;
&#xD;
               -  hemoglobin &gt;7g/dL&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for&#xD;
             the duration of protocol treatment. Should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she should inform her treating physician&#xD;
             immediately. A female of child-bearing potential is any woman (regardless of sexual&#xD;
             orientation, having undergone a tubal ligation, or remaining celibate by choice) who&#xD;
             meets the following criteria: has not undergone a hysterectomy or bilateral&#xD;
             oophorectomy; or has not been naturally postmenopausal for at least 12 consecutive&#xD;
             months (i.e., has had menses at any time in the preceding 12 consecutive months).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No concomitant therapy with any of the following: IL2, interferon, or other non-study&#xD;
             immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; or other&#xD;
             investigational therapies; all such therapies must have been discontinued &gt;4weeks&#xD;
             prior to registration.&#xD;
&#xD;
          -  No infection with HIV and no known history of hepatitis B or hepatitis C virus&#xD;
             indicating acute or chronic infection or active TB.&#xD;
&#xD;
          -  Patients are excluded if they have a history of any other malignancy from which the&#xD;
             patient has been disease-free for less than 2 years, with the exception of adequately&#xD;
             treated (Surgery or radiation) and cured basal or squamous cell skin cancer,&#xD;
             superficial bladder cancer, carcinoma in situ of the cervix, or localized&#xD;
             adenocarcinoma of the cervix.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          -  Patients must not be pregnant or nursing.&#xD;
&#xD;
          -  Patients are excluded if they have a history of prior treatment with ipilimumab,&#xD;
             CTLA-4 inhibitor or agonist, nivolumab, PD-1 or PD-L1 inhibitor.&#xD;
&#xD;
          -  Subjects who have had major surgery within 2 weeks prior to first dose of drug&#xD;
&#xD;
          -  Subjects who have had radiation therapy within 2 weeks prior to first dose of drug&#xD;
&#xD;
          -  Uncontrolled adrenal insufficiency or active chronic liver disease&#xD;
&#xD;
          -  Any history of CNS metastases that is not adequately treated (surgery or radiation )&#xD;
             &gt;14 days prior to registration.&#xD;
&#xD;
          -  Any active known or suspected autoimmune disease. Subjects with vitiligo, type I&#xD;
             diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring&#xD;
             hormone replacement, psoriasis not requiring systemic treatment, or conditions not&#xD;
             expected to recur in the absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  Any condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalent) or other immunosuppressive medications within 14 days prior to&#xD;
             the first dose of study drug. Inhaled steroids and adrenal replacement steroid doses&#xD;
             up to 10 mg daily prednisone equivalent are permitted (although not encouraged) in the&#xD;
             absence of active autoimmune disease.&#xD;
&#xD;
          -  Subjects with life expectancy &lt; 6 months&#xD;
&#xD;
          -  Subjects receiving any other investigational or standard antineoplastic agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Albuquerque, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

